Opinion statement All MPM patients with a good performance status should be considered
for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM …

Most patients affected by malignant pleural mesothelioma (MPM) are candidates for
chemotherapy during the course of the disease, as single modality treatment or within the …

Nearly all patients with malignant pleural mesothelioma (MPM) progress during or after
standard first-line treatment with pemetrexed plus a platinum compound. Second-line …

Malignant pleural mesothelioma (MPM) is an uncommon disease most often associated with
occupational asbestos exposure and is steadily increasing in worldwide incidence. Patients …

7040 Background: Chemotherapy is the only option for MPM. Cisplatin+ pemetrexed
became the standard in the first-line (FL), while the role of a second-line (SL) remains …

Opinion statement Unresectable or relapsed malignant pleural mesothelioma (MPM) has
dismal prognosis. First-line combination therapy with pemetrexed and a platinum analog …

This review summarises results of previously conducted clinical trials and subsequently
presents data arising from all phase II–III studies on chemotherapy for malignant pleural …

Malignant pleural mesothelioma (MPM) is a resistant form of lung cancer that is often related
to prior asbestos exposure. While surgical resection and radiotherapy techniques have been …

The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of
malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered …

Malignant pleural mesothelioma (MPM) is a disease usually unaffected by current
therapeutic strategies, but for the majority of patients, the use of systemic chemotherapeutic …